AC   CVCL_5711
DR   BTO; BTO:0001931
DR   EFO; EFO_0002815
DR   AddexBio; C0003016/4884
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-7721
DR   ArrayExpress; E-MTAB-7722
DR   BioSample; SAMN03470800
DR   CGH-DB; 9192-4
DR   ChEMBL-Cells; CHEMBL3308492
DR   ChEMBL-Targets; CHEMBL613536
DR   Cosmic; 998715
DR   Cosmic; 1019312
DR   Cosmic; 1037700
DR   Cosmic; 1086323
DR   Cosmic; 1127265
DR   Cosmic; 1517659
DR   Cosmic; 1588562
DR   Cosmic; 1945179
DR   DSMZ; ACC-757
DR   GEO; GSM33155
DR   GEO; GSM710427
DR   GEO; GSM710443
DR   GEO; GSM1059805
DR   IARC_TP53; 699
DR   Lonza; 107
DR   PharmacoDB; BJAB_102_2019
DR   Progenetix; CVCL_5711
DR   TOKU-E; 3575
DR   Wikidata; Q50348210
RX   PubMed=171663;
RX   PubMed=179629;
RX   PubMed=1915267;
RX   PubMed=3495441;
RX   PubMed=3518877;
RX   PubMed=4369887;
RX   PubMed=6231253;
RX   PubMed=6286763;
RX   PubMed=6600440;
RX   PubMed=7316467;
RX   PubMed=8344493;
RX   PubMed=8515068;
RX   PubMed=8558920;
RX   PubMed=23292937;
RX   PubMed=25485619;
RX   PubMed=29416618;
RX   PubMed=29666304;
RX   PubMed=30165192;
RX   PubMed=31160637;
CC   Part of: LL-100 blood cancer cell line panel.
CC   Characteristics: EBV-negative. Even so that the original tumor tissue was infected with the B95-8 strain of EBV.
CC   Doubling time: ~22 hours (PubMed=179629); ~40-60 hours (DSMZ).
CC   Sequence variation: Gene fusion; KMT2A-CLTC (PubMed=31160637).
CC   Sequence variation: TP53 p.His193Arg (c.578A>G) (ClinVar=VCV000184979) (PubMed=1915267; PubMed=8344493).
CC   Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
CC   Omics: Deep exome analysis.
CC   Omics: Deep RNAseq analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis.
ST   Source(s): DSMZ; PubMed=25877200
ST   Amelogenin: X
ST   CSF1PO: 8,10
ST   D13S317: 9,11
ST   D16S539: 9,11
ST   D18S51: 16,22
ST   D21S11: 27,28
ST   D3S1358: 16
ST   D5S818: 12,13
ST   D7S820: 10,11
ST   D8S1179: 15
ST   FGA: 27,28
ST   Penta D: 10,11
ST   Penta E: 7
ST   TH01: 7
ST   TPOX: 6,9
ST   vWA: 14,15 (DSMZ)
ST   vWA: 14,16 (PubMed=25877200)
DI   NCIt; C2912; Burkitt lymphoma
DI   ORDO; Orphanet_543; Burkitt lymphoma
OX   NCBI_TaxID=9606; ! Homo sapiens
SX   Female
AG   5Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 12-01-21; Version: 31
RX   PubMed=171663; DOI=10.1073/pnas.72.9.3518;
RA   Steinitz M., Klein G.;
RT   "Comparison between growth characteristics of an Epstein-Barr virus
RT   (EBV)-genome-negative lymphoma line and its EBV-converted subline in
RT   vitro.";
RL   Proc. Natl. Acad. Sci. U.S.A. 72:3518-3520(1975).
RX   PubMed=179629;
RA   Menezes J., Leibold W., Klein G., Clements G.B.;
RT   "Establishment and characterization of an Epstein-Barr virus
RT   (EBV)-negative lymphoblastoid B cell line (BJA-B) from an exceptional,
RT   EBV-genome-negative African Burkitt's lymphoma.";
RL   Biomedicine 22:276-284(1975).
RX   PubMed=1915267; DOI=10.1002/j.1460-2075.1991.tb07837.x;
RA   Farrell P.J., Allan G.J., Shanahan F., Vousden K.H., Crook T.;
RT   "p53 is frequently mutated in Burkitt's lymphoma cell lines.";
RL   EMBO J. 10:2879-2887(1991).
RX   PubMed=3495441; DOI=10.1002/eji.1830170503;
RA   Kanowith-Klein S., Saxon A., Uittenbogaart C.H.;
RT   "Constitutive production of B cell differentiation factor-like
RT   activity by human T and B cell lines.";
RL   Eur. J. Immunol. 17:593-598(1987).
RX   PubMed=3518877; DOI=10.3109/07357908609038260;
RA   Fogh J.;
RT   "Human tumor lines for cancer research.";
RL   Cancer Invest. 4:157-184(1986).
RX   PubMed=4369887; DOI=10.1073/pnas.71.8.3283;
RA   Klein G., Lindahl T., Jondal M., Leibold W., Menezes J., Nilsson K.,
RA   Sundstrom C.;
RT   "Continuous lymphoid cell lines with characteristics of B cells
RT   (bone-marrow-derived), lacking the Epstein-Barr virus genome and
RT   derived from three human lymphomas.";
RL   Proc. Natl. Acad. Sci. U.S.A. 71:3283-3286(1974).
RX   PubMed=6231253; DOI=10.1002/ijc.2910330407;
RA   Ehlin-Henriksson B., Klein G.;
RT   "Distinction between Burkitt lymphoma subgroups by monoclonal
RT   antibodies: relationships between antigen expression and type of
RT   chromosomal translocation.";
RL   Int. J. Cancer 33:459-463(1984).
RX   PubMed=6286763;
RA   Benjamin D., Magrath I.T., Maguire R.T., Janus C., Todd H.D.,
RA   Parsons R.G.;
RT   "Immunoglobulin secretion by cell lines derived from African and
RT   American undifferentiated lymphomas of Burkitt's and non-Burkitt's
RT   type.";
RL   J. Immunol. 129:1336-1342(1982).
RX   PubMed=6600440; DOI=10.1007/BF02617996;
RA   Uittenbogaart C.H., Cantor Y., Fahey J.L.;
RT   "Growth of human malignant lymphoid cell lines in serum-free medium.";
RL   In Vitro 19:67-72(1983).
RX   PubMed=7316467; DOI=10.1111/j.1469-1809.1980.tb00953.x;
RA   Povey S., Jeremiah S., Arthur E., Steel M., Klein G.;
RT   "Differences in genetic stability between human cell lines from
RT   patients with and without lymphoreticular malignancy.";
RL   Ann. Hum. Genet. 44:119-133(1980).
RX   PubMed=8344493; DOI=10.1096/fasebj.7.10.8344493;
RA   Bhatia K., Goldschmidts W., Gutierrez M.I., Gaidano G., Dalla-Favera R.,
RA   Magrath I.T.;
RT   "Hemi- or homozygosity: a requirement for some but not other p53
RT   mutant proteins to accumulate and exert a pathogenetic effect.";
RL   FASEB J. 7:951-956(1993).
RX   PubMed=8515068;
RA   Jain V.K., Judde J.-G., Max E.E., Magrath I.T.;
RT   "Variable IgH chain enhancer activity in Burkitt's lymphomas suggests
RT   an additional, direct mechanism of c-myc deregulation.";
RL   J. Immunol. 150:5418-5428(1993).
RX   PubMed=8558920;
RA   Dirks W.G., Zaborski M., Jager K., Challier C., Shiota M.,
RA   Quentmeier H., Drexler H.G.;
RT   "The (2;5)(p23;q35) translocation in cell lines derived from malignant
RT   lymphomas: absence of t(2;5) in Hodgkin-analogous cell lines.";
RL   Leukemia 10:142-149(1996).
RX   PubMed=23292937; DOI=10.1073/pnas.1205299110;
RA   Zhang J., Grubor V., Love C.L., Banerjee A., Richards K.L.,
RA   Mieczkowski P.A., Dunphy C., Choi W., Au W.Y., Srivastava G.,
RA   Lugar P.L., Rizzieri D.A., Lagoo A.S., Bernal-Mizrachi L., Mann K.P.,
RA   Flowers C., Naresh K., Evens A., Gordon L.I., Czader M.B., Gill J.I.,
RA   Hsi E.D., Liu Q., Fan A., Walsh K., Jima D., Smith L.L., Johnson A.J.,
RA   Byrd J.C., Luftig M.A., Ni T., Zhu J., Chadburn A., Levy S.,
RA   Dunson D.B., Dave S.S.;
RT   "Genetic heterogeneity of diffuse large B-cell lymphoma.";
RL   Proc. Natl. Acad. Sci. U.S.A. 110:1398-1403(2013).
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z., Liu H.,
RA   Degenhardt J., Mayba O., Gnad F., Liu J., Pau G., Reeder J., Cao Y.,
RA   Mukhyala K., Selvaraj S.K., Yu M., Zynda G.J., Brauer M.J., Wu T.D.,
RA   Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D.,
RA   Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S.,
RA   Zhang Z.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
RX   PubMed=29416618; DOI=10.18632/oncotarget.20378;
RA   Liu W., Chen J., Tamayo A.T., Ruan C.-G., Li L., Zhou S., Shen C.,
RA   Young K.H., Westin J., Davis R.E., Hu S., Medeiros L.J., Ford R.J.,
RA   Pham L.V.;
RT   "Preclinical efficacy and biological effects of the oral proteasome
RT   inhibitor ixazomib in diffuse large B-cell lymphoma.";
RL   Oncotarget 9:346-360(2018).
RX   PubMed=29666304; DOI=10.1158/1078-0432.CCR-17-3004;
RA   Pham L.V., Huang S.-J., Zhang H., Zhang J., Bell T., Zhou S., Pogue E.,
RA   Ding Z., Lam L., Westin J., Davis R.E., Young K.H., Medeiros L.J.,
RA   Ford R.J., Nomie K., Zhang L., Wang M.;
RT   "Strategic therapeutic targeting to overcome venetoclax resistance in
RT   aggressive B-cell lymphomas.";
RL   Clin. Cancer Res. 24:3967-3980(2018).
RX   PubMed=30165192; DOI=10.1016/j.canlet.2018.08.020;
RA   Qu C.-J., Kunkalla K., Vaghefi A., Frederiksen J.K., Liu Y.-D.,
RA   Chapman J.R., Blonska M., Bernal-Mizrachi L., Alderuccio J.P.,
RA   Lossos I.S., Landgraf R., Vega F.;
RT   "Smoothened stabilizes and protects TRAF6 from degradation: a novel
RT   non-canonical role of smoothened with implications in lymphoma
RT   biology.";
RL   Cancer Lett. 436:149-158(2018).
RX   PubMed=31160637; DOI=10.1038/s41598-019-44491-x;
RA   Quentmeier H., Pommerenke C., Dirks W.G., Eberth S., Koeppel M.,
RA   MacLeod R.A.F., Nagel S., Steube K., Uphoff C.C., Drexler H.G.;
RT   "The LL-100 panel: 100 cell lines for blood cancer studies.";
RL   Sci. Rep. 9:8218-8218(2019).